Trial Profile
An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Carcinoma; Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; TESARO
- 16 Jul 2020 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results (n=9) of intra-tumoral concentration of niraparib compared with plasma concentration in patients with Breast cancer were presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.